Google
SERA — SERA PROGNOSTICS INC (Healthcare >> Medical Devices)
SERA FAQ
What is SERA's ROE?
SERA PROGNOSTICS INC reports a Return on Equity (ROE) of -47.53%.
What is SERA's dividend yield?
SERA PROGNOSTICS INC offers a dividend yield of 0.00%.
What is SERA's Deepscope Quality Score?
Deepscope rates SERA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SERA?
Deepscope's AI Timing Score for SERA is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SERA belong to?
SERA PROGNOSTICS INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 2.29
Price
0.05
(2.00%)
Day Change
|
|
|---|
SERA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.29 |
| PBV / Sector |
1.32 / 7.50
GOOD
|
| Earning Per Share | -0.83 |
| PE / Sector |
N/A / 29.01
|
| PEG or PE/Growth / Sector |
N/A / 0.39
|
| Average 1M Daily Value |
0.16 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:09 |
| Symbol | SERA |
| Name | SERA PROGNOSTICS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 38.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 89.09 / 18,389.26 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Phone: 801 990 0520
Website: https://www.sera.com
Employees: 71
Sector: Healthcare >> Medical Devices
Description: Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
